Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
Shao Y et al.
Cancer Science, 2024
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Hayes TK et al.
Nature Communications, 2024
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.
Falk M et al.
Current Oncology (toronto, Ont.), 2023
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study.
Gu L et al.
Journal of Clinical Medicine, 2022
Multiple mutations in the EGFR gene in lung cancer: a systematic review.
Castañeda-González JP et al.
Translational Lung Cancer Research, 2022
Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
Wang JL et al.
Genes and Environment : the Official Journal of the Japanese Environmental Mutagen Society, 2022
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC et al.
Current Oncology (toronto, Ont.), 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG et al.
Clinical Lung Cancer, 2021
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Mao L et al.
Pathology Oncology Research : Por, 2021
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S et al.
Future Oncology (london, England), 2019
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
Kuiper JL et al.
British Journal of Cancer, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Klughammer B et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance.
Improta G et al.
Oncology Letters, 2016
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
Yam I et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
Nie W et al.
International Journal of Oncology, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation.
Masago K et al.
Case Reports in Oncology, 2010
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.
Chen Z et al.
Plos One, 2008
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Gu D et al.
Human Mutation, 2007
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X et al.
Journal of Medical Genetics, 2007
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Pedersen MW et al.
Ugeskrift for Laeger, 2006
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Sakurada A et al.
Clinical Lung Cancer, 2006
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Chen YR et al.
Oncogene, 2006
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004